Skip to main content

Karen Eastham and Ronald Matricaria

Premium

Karen Eastham has been appointed to the board of directors of Illumina, the company announced last week.

She is executive vice president, COO, and a member of the board of trustees of the Burnham Institute. Prior to that, she was senior vice president and CFO of Diversa.

Eastham holds an MBA and a BS from Indiana University. She also serves on the boards of directors of Tercica, Oncosis/Cyntellect, and Salmedix, as well on the board of UCSD Athena.


Ronald Matricaria has joined the board of directors of Invitrogen, replacing William Mercer, who is retiring.

Matricaria is the former chairman and CEO of St. Jude Medical. Before his term at St. Jude, he spent 23 years at Eli Lilly, where his last position was executive vice president of the pharmaceutical division and president of its North American operations. He also had held the position of CEO at Lilly subsidiary Cardiac Pacemakers.

Matricaria also serves on the boards of directors of Cyberonics, VistaCare, CardioDynamics, and is chairman of the board of Haemonetics.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.